Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Ionis Pharmaceuticals to post earnings of ($1.23) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 12:30 PM ET.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $84.29 on Wednesday. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The business’s 50 day moving average price is $80.67 and its two-hundred day moving average price is $68.64. The company has a market cap of $13.65 billion, a PE ratio of -49.88 and a beta of 0.29. Ionis Pharmaceuticals has a twelve month low of $23.95 and a twelve month high of $86.74.

Analysts Set New Price Targets

IONS has been the topic of a number of recent analyst reports. Piper Sandler boosted their target price on Ionis Pharmaceuticals from $77.00 to $87.00 and gave the stock an “overweight” rating in a report on Friday. Bank of America raised their price target on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Barclays initiated coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $95.00 price objective for the company. Needham & Company LLC increased their price objective on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Wall Street Zen cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $86.95.

Insider Buying and Selling

In other news, EVP Shannon L. Devers sold 44,199 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $85.08, for a total transaction of $3,760,450.92. Following the completion of the sale, the executive vice president owned 17,494 shares of the company’s stock, valued at approximately $1,488,389.52. This represents a 71.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Joseph H. Wender sold 28,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the completion of the transaction, the director directly owned 36,035 shares in the company, valued at $2,912,348.70. This trade represents a 43.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 460,714 shares of company stock worth $37,295,131. 2.71% of the stock is owned by company insiders.

Institutional Trading of Ionis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in IONS. Quarry LP bought a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $38,000. Johnson Financial Group Inc. acquired a new position in Ionis Pharmaceuticals in the 3rd quarter worth about $44,000. Danske Bank A S bought a new position in Ionis Pharmaceuticals in the third quarter valued at about $92,000. Comerica Bank boosted its stake in shares of Ionis Pharmaceuticals by 35.3% during the third quarter. Comerica Bank now owns 2,187 shares of the company’s stock valued at $143,000 after purchasing an additional 570 shares in the last quarter. Finally, Voleon Capital Management LP bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth about $200,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.